Evidence map›Paper›PMID 36676675›Full record

ArticleMedicina (Kaunas, Lithuania)2022

Long-Term Outcome of Patients with Stage II and III Muscle-Invasive Urothelial Bladder Cancer after Multimodality Approach. Which Is the Best Option?

Oana Gabriela Trifanescu, Laurentia Nicoleta Gales, Mihai Andrei Paun, Natalia Motas, Serban Andrei Marinescu, Ion Virtosu, Raluca Alexandra Trifanescu, Mirela Gherghe, Liviu Bilteanu, Camelia Cristina Diaconu and 1 more

Abstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Disitamab vedotinFrontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Oana Gabriela TrifanescuDepartment of Oncology, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.ORCID 0000-0001-9566-7067
Laurentia Nicoleta GalesDepartment of Oncology, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.ORCID 0000-0002-0414-1607
Mihai Andrei PaunInstitute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest, Radiotherapy II, 022328 Bucharest, Romania.
Natalia MotasInstitute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest, Thoracic Surgery, 022328 Bucharest, Romania.ORCID 0000-0001-6556-3734
Serban Andrei MarinescuInstitute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest, Oncologic Surgery I, 022328 Bucharest, Romania.
Ion VirtosuInstitute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest, Radiotherapy II, 022328 Bucharest, Romania.
Raluca Alexandra TrifanescuInstitute of Endocrinology "C. I Parhon", 011863 Bucharest, Romania.
Mirela GhergheInstitute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest, Nuclear Medicine, 022328 Bucharest, Romania.ORCID 0000-0003-4293-0428
Liviu BilteanuInstitute of Oncology "Prof. Dr. Al. Trestioreanu" Bucharest, Radiotherapy II, 022328 Bucharest, Romania.
Camelia Cristina DiaconuClinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania.ORCID 0000-0001-6837-260X
Rodica Maricela AnghelDepartment of Oncology, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsHumansMiddle AgedMusclesNeoadjuvant TherapyNeoplasm InvasivenessRetrospective StudiesTreatment Outcomebladder cancerchemoradiotherapymultimodality treatmentneoadjuvant chemotherapy

Identifiers

PMID36676675
PMCPMC9865683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.